1. Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., et al. (2002). Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis and Rheumatology, 46(12), 3143–3150.
2. Elliott, M. J., Maini, R. N., Feldmann, M., Longfox, A., Charles, P., Katsikis, P., et al. (1993). Treatment of rheumatoid-arthritis with chimeric monoclonal-antibodies to tumor-necrosis-factor-alpha. Arthritis and Rheumatism, 36(12), 1681–1690.
3. Feldmann, M., & Maini, R. N. (2003). TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune disease. Nature Medicine, 9, 1245–1250.
4. Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., Kavanaugh, A., ADACTA Study Investigators. (2013). Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet, 381(9877), 1541–1550.
5. Gershwin, M. E., Ohsugi, Y., Ahmed, A., Castles, J. J., Scibienski, R., & Ikeda, R. M. (1980). Studies of congenitally immunologically mutant New-Zealand mice. IV. Development of autoimmunity in congenitally athymic (nude) New-Zealand black x white F1-hybrid mice. Journal of Immunology, 125(3), 1189–1195.